In a previous study, a bispecific T-cell engager system (BiTE) was used to bridge T cells (through CD3 specificity) to tumor cells expressing tumor-associated antigens (such as HER2), and then, BiTE was integrated into OVs to construct those with multiple immunoregulatory effects, which can release BiTE into tumor cells and induce T-cell-mediated tumor cell killing (85). Here, ERBB2 is linked to neoplasm.